Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | PRMT5 | O14744 | 5/20 | 0.36 |
| ▸ | WDR77 | Q9BQA1 | 5/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.35 |
| ▸ | BTK | Q06187 | 2/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19086008 | 0.88 | KDM1A (0.42) | KDM1AALDH1A1PRMT5WDR77TDP1 | |
| SCHEMBL19086987 | 0.88 | KDM1A (0.38) | KDM1AMAPTPRMT5WDR77HDAC6 | |
| SCHEMBL19086335 | 0.86 | HDAC6 (0.39) | KMT2APRMT5WDR77TDP1HDAC6 | |
| SCHEMBL19086218 | 0.85 | KDM1A (0.48) | KDM1AKMT2AMAPTLMNAALDH1A1 | |
| SCHEMBL19086244 | 0.84 | HCRTR2 (0.39) | KDM1AMAPTLMNAALDH1A1RAB9A | |
| SCHEMBL19086007 | 0.84 | PRMT5 (0.40) | KMT2AMAPTALDH1A1PRMT5WDR77 | |
| SCHEMBL19086242 | 0.83 | KDM1A (0.41) | KDM1AMAPTLMNAALDH1A1RAB9A | |
| SCHEMBL19086009 | 0.83 | KMT2A (0.42) | KMT2APRMT5WDR77MEN1SMN1; SMN2 | |
| SCHEMBL19086194 | 0.82 | PRMT5 (0.43) | KMT2APRMT5WDR77HCRTR2 | |
| SCHEMBL19086201 | 0.82 | PRMT5 (0.40) | ALDH1A1PRMT5WDR77HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017114275-A1 | COMPOUND FOR INHIBITING ROCK, PREPARATION METHOD AND USE OF SAME | 成都先导药物开发有限公司 | 2017-07-06 | — | — | WO | disclosed |
| US-20150290228-A1 | ORAL FORMULATIONS OF CYTIDINE ANALOGS AND METHODS OF USE THEREOF | CELGENE CORPORATION | 2015-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150290228-A1 | ORAL FORMULATIONS OF CYTIDINE ANALOGS AND METHODS OF USE THEREOF | BCL6, BCL3, BCL9 | KDM1A 1483/4885KMT2A 2359/4885MAPT 3941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.